Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
Patients with T2DM exhibit a significant incidence of gastrointestinal adverse events associated with semaglutide use. The presence of gastrointestinal comorbidities, alcohol consumption, and α-glucosidase inhibitor therapy are independent risk factors. The developed nomogram effectively predicts the likelihood of semaglutide-related gastrointestinal adverse events in this patient population.
Authors
- Guoliang Meng (ORCID: https://orcid.org/0000-0002-8523-6543)
- Weixia Jian (ORCID: https://orcid.org/0000-0002-4421-4284)
- Zhongyu Yuan (ORCID: https://orcid.org/0000-0002-2920-9671)
- Yi‐Rong Chen (ORCID: https://orcid.org/0000-0002-4307-3002)
- Ling Zhu (ORCID: https://orcid.org/0000-0002-6559-0967)
- Lihua Gu (ORCID: https://orcid.org/0000-0002-6392-1128)
- Deyong Yue
- Xuesheng Hua (ORCID: https://orcid.org/0000-0003-2172-3956)
- Cheng Wang (ORCID: https://orcid.org/0000-0002-1834-2119)
Institutions
- Nantong University (CN)
- Wuxi No.2 People's Hospital (CN)
- Shanghai University of Medicine and Health Sciences (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3389/fendo.2025.1684395
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29